Cinel A, Wittenberg L, Minucci D
Service of Gynecologic Oncology and Cytodiagnostics, Institute of Gynecology, Padua University, Italy.
Clin Exp Obstet Gynecol. 1991;18(2):91-7.
In a series of 131 patients we evaluated the effects of medical therapy with beta-Interferon cream in patients with cervical Human Papilloma Virus (HPV) infection, which in some cases, was associated with CIN. Treatment consisted of the direct daily application of 1,000,000 IU beta-Interferon cream to colposcopically positive areas over a period of 15 days. At intervals of 1, 6, 12 and 24 months following treatment, cytohistological tests were carried out to assess the effects of treatment. At the 24-month control, the overall percentage for regression was 79.57% of cases. Regression was observed in 58.33% of patients with cytohistological changes associated with HPV without atypia, and in 69.85% of patients with HPV with atypia (38.9% total regression). The regression pattern for CIN lesions was as follows: in CIN lesions, regression occurred in 85.36%, in CIN II in 84.20%, and 37.5% of CIN III cases showed total regression.
在一组131例患者中，我们评估了β-干扰素乳膏药物治疗对宫颈人乳头瘤病毒（HPV）感染患者的疗效，在某些情况下，该感染与宫颈上皮内瘤变（CIN）相关。治疗方法为每天直接在阴道镜检查阳性区域涂抹100万国际单位的β-干扰素乳膏，持续15天。治疗后1、6、12和24个月时，进行细胞组织学检查以评估治疗效果。在24个月的对照期，病例的总体消退率为79.57%。在无异型性的HPV相关细胞组织学改变患者中，58.33%观察到消退；在有异型性的HPV患者中，69.85%观察到消退（总消退率为38.9%）。CIN病变的消退模式如下：在CIN I病变中，85.36%出现消退；在CIN II病变中，84.20%出现消退；37.5%的CIN III病例完全消退。
